US contemplates changes to prevent another tainted heparin-like event
This article was originally published in SRA
Executive Summary
At a time when Republicans are seeking to cut more than $240 million from the US Food and Drug Administration's budget, the agency is facing an enormous challenge keeping up with inspections of foreign facilities where US drugs are made – with the number of those sites increasing 185% over the past decade – while also combating the rising problem of counterfeit medicines reaching the US supply chain.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.